PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

David J. Pinato,Alessio Cortellini,Madhava Pai,Duncan Spalding,Thomas Talbot,Robert D. Goldin,Aneta Gupta,Tom Cole,Caroline Ward,Vincent S. Yip,Tony Dhillon,Sarah Slater,Mikael H. Sodergren,Paul Tait,Nagy A. Habib,Robert J. Thomas,Rohini Sharma

PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

2021

David J. Pinato
Alessio Cortellini
Madhava Pai
Duncan Spalding
Thomas Talbot
Robert D. Goldin
Aneta Gupta
Tom Cole
Caroline Ward
Vincent S. Yip
Tony Dhillon
Sarah Slater
Mikael H. Sodergren
Paul Tait
Nagy A. Habib
Robert J. Thomas
Rohini Sharma

e16131Background: There are no approved peri-operative anti‐cancer therapies for patients with hepatocellular cancer (HCC) who are candidates for liver resection (LR). Combination immunotherapy ind...

Keywords:

Internal medicine
Medicine
Ipilimumab
Hepatocellular carcinoma
Nivolumab
hepatocellular cancer
Oncology
combination immunotherapy
Resection

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations